Intensivmedizin und Notfallmedizin

, Volume 46, Issue 6, pp 415–420 | Cite as

Akutes Rechtsherzversagen

Diagnostik und Therapie
Leitthema
First Online:
Received:
Accepted:

Zusammenfassung

Die ansteigende Prävalenz prädisponierender Erkrankungen führt dazu, dass das akute Rechtsherzversagens mit zunehmender Häufigkeit zur kardiozirkulatorischen Dekompensation führt. Durch diagnostische Verfahren wie der Analyse von Biomarkern sowie neuerer echokardiographischer und hämodynamischer Parameter kann die Funktion des rechten Ventrikels, die im Bereich der Bildgebung aufgrund der komplexen Anatomie schwierig ist, besser beschrieben werden. Therapeutisch steht weiterhin die Behebung der Ursache im Vordergrund. Die klassischen Therapieoptionen werden zunehmend durch Medikamente ergänzt, die eine selektive Steuerung des pulmonalvaskulären Widerstandes erlauben und die Kopplung des rechten Ventrikels an die pulmonale Strombahn (ventrikulovaskuläre Kopplung) verbessern. Problematisch bleiben weiterhin die geringe Studienzahl zum akuten Rechtsherzversagen und die damit einhergehende geringe Evidenz vieler Empfehlungen.

Schlüsselwörter

Akutes Rechtsherzversagen Pulmonalvaskulärer Widerstand (PVR) Rechtsventrikulärer Cardiac Power Index (rvCPI) Levosimendan Kardiozirkulatorische Dekompensation 

Acute right ventricular failure

Diagnosis and treatment

Abstract

Due to the increasing prevalence of predisposing conditions, right ventricular failure is increasingly encountered as the cause of cardiocirculatory decompensation. Analysis of biomarkers and newer echocardiographic and hemodynamic parameters allow for a better characterization of right ventricular function, which is deemed difficult with imaging due to the complex anatomy of the right ventricle. Therapeutically, the treatment of the underlying cause is mandatory. Classical therapeutic options are supplemented by medications that allow selective steering of pulmonary vascular resistance and improve ventriculo-vascular coupling. There are still concerns about the small number of studies in acute right ventricular failure and the low grade evidence for the treatment recommendations.

Keywords

Acute right ventricular failure  Pulmonary vascular resistance (PVR)  Right ventricular Cardiac Power Index (rvCPI)  Levosimendan Cardiocirculatory decompensation 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Starr I, Jeffers WA, Meade RH (1943) The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease. Am Heart J 26:291–301CrossRefGoogle Scholar
  2. 2.
    Kagan A (1952) Dynamic responses of the right ventricle following extensive damage by cauterization. Circulation 5:816–823PubMedGoogle Scholar
  3. 3.
    Goldstein JA, Vlahakes GJ, Verrier ED et al (1982) The role of right ventricular systolic dysfunction and elevated intrapericardial pressure in the genesis of low output in experimental right ventricular infarction. Circulation 65:513–522PubMedGoogle Scholar
  4. 4.
    Zehender M, Kasper W, Kauder E et al (1993) Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 328:981–988PubMedCrossRefGoogle Scholar
  5. 5.
    Lega JC, Lacasse Y, Lakhal L, Provencher S (2009) Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax (in press)Google Scholar
  6. 6.
    Torbicki A, Kurzyna M, Kuca P et al (2003) Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844–848PubMedCrossRefGoogle Scholar
  7. 7.
    Nagaya N, Nishikimi T, Okano Y et al (1998) Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31:202–208PubMedCrossRefGoogle Scholar
  8. 8.
    Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870PubMedGoogle Scholar
  9. 9.
    Kirkpatrick JN, Vannan MA, Narula J, Lang RM (2007) Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol 50:381–396PubMedCrossRefGoogle Scholar
  10. 10.
    Kjaergaard J, Akkan D, Iversen KK et al (2007) Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail 9:610–616PubMedCrossRefGoogle Scholar
  11. 11.
    Russ M, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med (in press)Google Scholar
  12. 12.
    Bowers TR, O’Neill WW, Grines C et al (1998) Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med 338:933–940PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts DH, Lepore JJ, Maroo A (2001) Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 120:1547–1555PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein JA, Harada A, Yagi Y (1990) Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility, and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 16:181–189PubMedCrossRefGoogle Scholar
  15. 15.
    Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U et al (1998) Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 114:780–786PubMedCrossRefGoogle Scholar
  16. 16.
    Wilkens H, Guth A, Konig J et al (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222PubMedCrossRefGoogle Scholar
  17. 17.
    Matot I, Gozal Y (n d) Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 125:644–651Google Scholar
  18. 18.
    Kerbaul F, Rondelet B, Motte S et al (2004) Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 32:1035–1040PubMedCrossRefGoogle Scholar
  19. 19.
    Kwak YL, Lee CS, Park YH (n d) The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia 57:9–14Google Scholar
  20. 20.
    Kerbaul F, Gariboldi V, Giorgi R et al (2007) Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med 35:1948–1954PubMedCrossRefGoogle Scholar
  21. 21.
    Kerbaul F, Rondelet B, Demester JP et al (2006) Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 34:2814–2819PubMedCrossRefGoogle Scholar
  22. 22.
    Post F, Mertens D, Peetz D et al (2006) Levosimendan for acute pulmonary embolism. Intensivmed 43:636–642CrossRefGoogle Scholar
  23. 23.
    Cicekcioglu F, Parlar AI, Ersoy O et al (2008) Levosimendan and severe pulmonary hypertension during open heart surgery. Gen Thorac Cardiovasc Surg 56:563–565PubMedCrossRefGoogle Scholar

Copyright information

© Spinger 2009

Authors and Affiliations

  1. 1.Universitätsklinik und Poliklinik für Innere Medizin IIIUniversitätsklinikum Halle (Saale)Halle (Saale)Deutschland

Personalised recommendations